NIS - libdoc.who.int - World Health Organization

WHO monographs on medicinal plants commonly used in the Newly Independent States (NIS)
66. Abdul-Ghani AS et al. Hypotensive effect of Crataegus oxyacantha. International
Journal of Crude Drug Research, 1987, 25:216–220.
67. Fehri B et al. Valeriana officinalis et Crataegus oxyacantha toxicité par administrations
réitérées et investigations pharmacologiques. Journale de
Pharmacie de Belgique, 1991, 46:165–176.
68. Liévre M et al. Étude des effets cardiovasculaires de l’hyperoside extrait de
l’Aubépine chez le chien anesthésié. Annales pharmaceutiques françaises,
1985, 5:471–477.
69. Rácz-Kotilla E et al. Hypotensive and beta-blocking effect of procyanidins
of Crataegus monogyna. Planta Medica, 1980, 39:239.
70. Bahorun T et al. Antioxidant activities of Crataegus monogyna extracts.
Planta Medica, 1994, 60:323–328.
71. Bahorun T et al. Oxygen species scavenging activity of phenolic extracts
from hawthorn fresh plant organs and pharmaceutical preparations. Arzneimittel-Forschung,
1996, 46:1086–1089.
72. Rakotoarison DA et al. Antioxidant activities of polyphenolic extracts from
flowers, in vitro callus and cell suspension culture of Crataegus monogyna.
Pharmazie, 1997, 52:60–64.
73. Petkov E et al. Inhibitory effect of some flavonoids and flavonoid mixtures
on cyclic AMP phosphodiesterase activity of rat heart. Planta Medica, 1981,
43:183–186.
74. Schüssler M et al. Comparison of the flavonoids occurring in Crataegus species
and inhibition of 3’,5’-cyclic adenosine monophosphate phosphodiesterase.
Planta Medica, 1991, 57 (Suppl. 2):A133.
75. Schüssler M et al. Cardiac effects of flavonoids from Crataegus species.
Planta Medica, 1993, 59 (Suppl. 2):A688.
76. Vibes J et al. Inhibition of thromboxane A2 biosynthesis in vitro by the main
components of Crataegus oxyacantha (hawthorn) flower heads. Prostaglandins,
Leukotrienes and Essential Fatty Acids, 1994, 50:173–175.
77. Vibes J et al. Effects of a methanolic extract from Crataegus oxyacantha
blossoms on TXA 2
and PGI 2
synthesising activities of cardiac tissue. Medical
Science Research, 1993, 21:435–436.
78. Wrocinski T. Determination of the activity of spasmolytic drugs with reference
to the papaverine standard. Biuletyn Instytutu Roslin Lecznniczych,
1960, 6:236.
79. Beretz A et al. Choix de méthodes pharmacologiques pour l’étude des activités
de l’aubépine. Plantes médicinales et Phytothérapie, 1978, 12:305–314.
80. Della Loggia R et al. Depressive effect of Crataegus oxyacantha L. on central
nervous system in mice. Science and Pharmacy, 1983, 51:319–324.
81. Borkowski B. Diuretic action of several flavone drugs. Planta Medica, 1960,
8:95–104.
82. Schlegelmilch R, Heywood R. Toxicity of Crataegus (hawthorne) extract
(WS 1442). Journal of the American College of Toxicology, 1994, 13:103–111.
110